On Oct 24, major Wall Street analysts update their ratings for $Quest Diagnostics (DGX.US)$, with price targets ranging from $165 to $185.
Citi analyst Patrick B Donnelly maintains with a buy rating, and adjusts the target price from $165 to $185.
Barclays analyst Stephanie Davis maintains with a hold rating, and adjusts the target price from $154 to $168.
Evercore analyst Elizabeth Anderson CFA maintains with a hold rating, and maintains the target price at $165.
Baird analyst Eric Coldwell upgrades to a buy rating, and adjusts the target price from $157 to $182.
Truist Financial analyst David S Macdonald maintains with a hold rating, and adjusts the target price from $165 to $172.
Furthermore, according to the comprehensive report, the opinions of $Quest Diagnostics (DGX.US)$'s main analysts recently are as follows:
The revised guidance for Quest Diagnostics is primarily attributed to the integration of LifeLabs, accompanied by sustained high utilization trends. The defensive characteristics of Quest, especially around an election cycle, and the more secure estimates for future years are viewed positively.
Quest Diagnostics delivered a strong third-quarter performance, characterized by exceeding expectations and maintaining earnings guidance even amid hurricane challenges. Additionally, the company provided an encouraging preliminary outlook for fiscal year 2025.
The elevated estimates for Quest Diagnostics come on the heels of robust third-quarter performances and a strong preliminary outlook for 2025. The company's prospects for earnings remain promising, bolstered by consistent healthcare utilization trends, market share expansions, and a favorable mix.
The lab sector is viewed positively for its prospects in 2025, with the belief that there shouldn't be hesitation in favoring one company on the basis of cost alone. Quest Diagnostics is recognized for having several catalysts that may contribute to hastened growth in 2025, bolstered by a series of eight acquisitions expected to complete in 2024, which should sustain the company's momentum into the following year.
Here are the latest investment ratings and price targets for $Quest Diagnostics (DGX.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月24日，多家華爾街大行更新了$奎斯特診療 (DGX.US)$的評級，目標價介於165美元至185美元。
花旗分析師Patrick B Donnelly維持買入評級，並將目標價從165美元上調至185美元。
巴克萊銀行分析師Stephanie Davis維持持有評級，並將目標價從154美元上調至168美元。
Evercore分析師Elizabeth Anderson CFA維持持有評級，維持目標價165美元。
貝雅分析師Eric Coldwell上調至買入評級，並將目標價從157美元上調至182美元。
儲億銀行分析師David S Macdonald維持持有評級，並將目標價從165美元上調至172美元。
此外，綜合報道，$奎斯特診療 (DGX.US)$近期主要分析師觀點如下：
奎斯特診療的修訂指引主要歸因於LifeLabs的整合，以及持續高利用率趨勢的伴生。尤其是在選舉週期期間，奎斯特的防禦特性，以及未來年度更加可靠的估計被積極看待。
奎斯特診療在第三季度表現強勁，超出預期並保持盈利指引，即使在颶風挑戰中依然如此。此外，該公司對2025財年提供了令人鼓舞的初步展望。
奎斯特診療的預估提升是基於強勁的第三季度表現和2025年初步展望。該公司的盈利前景仍然令人看好，受益於穩定的醫療保健利用趨勢、市場份額擴張和有利的組合。
實驗室板塊在2025年的前景被看好，認爲不應僅基於成本選擇一家公司。奎斯特診療因具備幾個可能促進2025年增長加速的催化劑而受到認可，這受益於預計將在2024年完成的八起收購交易，這將有助於該公司的勢頭持續到隨後的一年。
以下爲今日5位分析師對$奎斯特診療 (DGX.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
